Albarel et al. [23] summarized several longitudinal cohort studies of ICI-induced hypophysitis including 76 patients who received anti-CTLA-4 antibodies, anti-programmed death receptor-1(PD-1) antibodies, antibodies targeting PD-1 ligand (PD-L1), or combination treatments. Here, CTLA4 is linked to hypophysitis.